Direct Intra-arterial thrombectomy in order to Revascularize AIS patients with large vessel occlusion Efficiently in Chinese Tertiary hospitals: a Multicenter randomized clinical Trial (DIRECT-MT)

Project leaders:
Liu Jianmin, Deng Benqiang
Charles Majoie, Yvo Roos

Sponsor: Changhai Hospital Affiliated to the Second Military Medical University
CRO: Cardiovascular Chinese Research Center
Protocol No.: CH01
Version No.: V3.0
Date: August 20, 2019

Statement of Confidentiality
The information contained in this document involves trade secrets and business information, which is confidential or proprietary and shall not be disclosed by any person unless required by regulations. Any individual who has access to the document shall be aware that the document is proprietary or confidential and shall not disclose the document without authorization. The above restrictions on the confidentiality of the document will apply to any proprietary or confidential data provided to you in the future.
**Protocol title:**

Direct Intra-arterial thrombectomy in order to Revascularize AIS patients with large vessel occlusion Efficiently in Chinese Tertiary hospitals: a Multicenter randomized clinical Trial (DIRECT-MT)

<table>
<thead>
<tr>
<th>Protocol ID</th>
<th>CH01</th>
</tr>
</thead>
<tbody>
<tr>
<td>Version</td>
<td>3.0</td>
</tr>
<tr>
<td>Date</td>
<td>August 20, 2019</td>
</tr>
<tr>
<td>Project leaders</td>
<td>Prof dr Liu Jianmin, Changhai Hospital Affiliated to the Second Military Medical University</td>
</tr>
<tr>
<td></td>
<td>Prof dr Deng Benqiang, Changhai Hospital Affiliated to the Second Military Medical University</td>
</tr>
<tr>
<td></td>
<td>Prof dr Charles Majoie, Academisch Medisch Centrum bij de Universiteit van Amsterdam (AMC)</td>
</tr>
<tr>
<td></td>
<td>Prof dr Yvo Roos, Academisch Medisch Centrum bij de Universiteit van Amsterdam (AMC)</td>
</tr>
<tr>
<td>Coordinating investigators</td>
<td>Prof dr Yang Pengfei, Changhai Hospital Affiliated to the Second Military Medical University</td>
</tr>
<tr>
<td></td>
<td>Prof dr Zhang Yongwei, Changhai Hospital Affiliated to the Second Military Medical University</td>
</tr>
<tr>
<td>Sponsor</td>
<td>Changhai Hospital Affiliated to the Second Military Medical University</td>
</tr>
<tr>
<td>CRO</td>
<td>Cardiovascular Chinese Research Center</td>
</tr>
</tbody>
</table>
I have read this trial protocol carefully and recognize that this protocol covers all the necessary contents for the implementation of the trial. I will conduct the study according to the protocol and complete the study within the specified period of time.

I will provide copies of this study protocol and all relevant information to all staff who assist me in conducting this study. I will discuss these materials with them to ensure that they fully understand the test drug and how to conduct the trial.
# Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>List of abbreviations and definitions of terms</td>
<td>7</td>
</tr>
<tr>
<td><strong>SUMMARY</strong></td>
<td>9</td>
</tr>
<tr>
<td>1. Introduction and rationale</td>
<td>11</td>
</tr>
<tr>
<td>2. Study objectives</td>
<td>12</td>
</tr>
<tr>
<td>3. Study design</td>
<td>12</td>
</tr>
<tr>
<td>4. Study population</td>
<td>12</td>
</tr>
<tr>
<td>4.1. Population (Base)</td>
<td>12</td>
</tr>
<tr>
<td>4.2. Participating centers and center eligibility</td>
<td>12</td>
</tr>
<tr>
<td>4.3. Inclusion criteria</td>
<td>13</td>
</tr>
<tr>
<td>4.4. Exclusion criteria</td>
<td>13</td>
</tr>
<tr>
<td>4.5. Sample size calculation</td>
<td>14</td>
</tr>
<tr>
<td>5. Treatment of subjects</td>
<td>14</td>
</tr>
<tr>
<td>5.1. Investigational treatment</td>
<td>14</td>
</tr>
<tr>
<td>5.2. Use of co-intervention</td>
<td>15</td>
</tr>
<tr>
<td>5.3. Escape medication</td>
<td>15</td>
</tr>
<tr>
<td>6. Investigational product</td>
<td>15</td>
</tr>
<tr>
<td>6.1. Name and description of investigational product</td>
<td>15</td>
</tr>
<tr>
<td>6.2. Summary of findings from clinical studies</td>
<td>15</td>
</tr>
<tr>
<td>6.3. Summary of known and potential risks and benefits</td>
<td>15</td>
</tr>
<tr>
<td>6.4. Description and justification of route of administration and dosage</td>
<td>16</td>
</tr>
<tr>
<td>7. Non-investigational product</td>
<td>16</td>
</tr>
<tr>
<td>7.1. Name and description of non-investigational products</td>
<td>16</td>
</tr>
<tr>
<td>7.2. Summary of findings from clinical studies</td>
<td>16</td>
</tr>
<tr>
<td>7.3. Summary of known and potential risks and benefits</td>
<td>16</td>
</tr>
<tr>
<td>8. Method</td>
<td>16</td>
</tr>
<tr>
<td>8.1. Study outcomes</td>
<td>16</td>
</tr>
<tr>
<td>8.1.1. Main study outcome</td>
<td>16</td>
</tr>
<tr>
<td>8.1.2. Secondary outcomes</td>
<td>17</td>
</tr>
<tr>
<td>8.1.3. Safety outcomes</td>
<td>17</td>
</tr>
<tr>
<td>8.1.4. Other study parameters</td>
<td>17</td>
</tr>
<tr>
<td>8.2. Randomization, blinding and treatment allocation</td>
<td>18</td>
</tr>
<tr>
<td>8.3. Study procedures</td>
<td>18</td>
</tr>
<tr>
<td>8.4. Withdrawal of individual subjects</td>
<td>18</td>
</tr>
<tr>
<td>8.5. Premature termination of the study</td>
<td>18</td>
</tr>
<tr>
<td>9. Safety reporting</td>
<td>19</td>
</tr>
<tr>
<td>9.1. Temporary halt for reasons of subject safety</td>
<td>19</td>
</tr>
</tbody>
</table>
9.2. AEs, SAEs and SUSARs
   9.2.1. Adverse events (AEs) 19
   9.2.2. Serious adverse events (SAEs) 19
9.3. Follow-up of adverse events 20
9.4. Data Safety Monitoring Board (DSMB) 20
10. Statistical analysis 20
   10.1. Statistical analysis 20
   10.2. Subgroup analysis 21
   10.3. Interim analysis 21
11. Ethical considerations 21
   11.1. Regulation statement 21
   11.2. Recruitment and consent 21
   11.3. Problems of minors or incapacitated subjects 22
   11.4. Benefits and risks assessment, group relatedness 22
   11.5. Compensation for injury 22
12. Administrative aspects, monitoring and publication 22
   12.1. Handling and storage of data and documents 22
   12.2. Monitoring and quality assurance 22
   12.3. Amendment 23
   12.4. Annual progress report 23
   12.5. Temporary halt and (prematurely) end of study report 23
   12.6. Public disclosure and publication policy 23
13. References 24
14. Table 28
   Table 1 Modified Rankin Scale (35) 28
   Table 2 Extended Treatment In Cerebral Ischemia (Etici) Scale (36) 29
   Table 3 NIH Stroke Scale 30
   Table 4 Barthel Index (40) 34
   Table 5 EUROQOL 5D-5L (39) 36
   Table 6 Clot Burden Score for CTA and MRA (46) 38
   Table 7 Collateral Score (43) 38
   Table 8 Classification pf Infarct in a New Territory (42) 39
   Table 9 Report of Suspicious Medical Device Adverse Events 40
15. Figure 42
   Figure 1 DIRECT-MT Trial Logo 42
   Figure 2 Patient Flow in the Trial 42
16. Appendix 43
16.1 Study committees

Steering Committee 43
Data Safety Monitoring Board 43
Imaging Assessment Committee 43
Adverse Event Adjudication Committee 43
Outcome Committee 44

16.2 DIRECT-MT recommendations of the Steering Committee with regard to type of mechanical thrombectomy and use of thrombolytic agents during endovascular procedures.

General 44
Neuroimaging 44
Additional thrombolytic agents, dose and type 44
Type of mechanical thrombectomy device(s) 44

16.3 Imaging requirements

16.3.1 Minimum baseline imaging requirements 45
When 45
How 45

16.3.2 Intervention-related angiographic imaging 45
When 45
How 46

16.3.3 Minimum follow-up imaging requirements 47
When 47
How 47
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>Adverse event</td>
</tr>
<tr>
<td>AIS</td>
<td>Acute ischemic stroke</td>
</tr>
<tr>
<td>AR</td>
<td>Adverse Reaction</td>
</tr>
<tr>
<td>ASA</td>
<td>Acetyl salicylic acid</td>
</tr>
<tr>
<td>CT</td>
<td>Computed tomography</td>
</tr>
<tr>
<td>CTA</td>
<td>Computed tomography angiography</td>
</tr>
<tr>
<td>CV</td>
<td>Curriculum Vitae</td>
</tr>
<tr>
<td>DSMB</td>
<td>Data Safety Monitoring Board</td>
</tr>
<tr>
<td>EC</td>
<td>Ethics committee</td>
</tr>
<tr>
<td>EU</td>
<td>European Union</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>IAT</td>
<td>Intra-arterial treatment</td>
</tr>
<tr>
<td>IB</td>
<td>Investigator's Brochure</td>
</tr>
<tr>
<td>ICF</td>
<td>Informed Consent Form</td>
</tr>
<tr>
<td>ICH</td>
<td>Intracerebral hemorrhage</td>
</tr>
<tr>
<td>IMP</td>
<td>Investigational Medicinal Product</td>
</tr>
<tr>
<td>IU</td>
<td>International standard unit</td>
</tr>
<tr>
<td>IV</td>
<td>Intravenous</td>
</tr>
<tr>
<td>MRI</td>
<td>Magnetic resonance imaging</td>
</tr>
<tr>
<td>NIHSS</td>
<td>NIH Stroke Scale test</td>
</tr>
<tr>
<td>(S) AE</td>
<td>(Serious) adverse event</td>
</tr>
<tr>
<td>sICH</td>
<td>Symptomatic intracerebral hemorrhage</td>
</tr>
</tbody>
</table>

**Sponsor**

The sponsor is the party that commissions the organization or performance of the research, for example a pharmaceutical company, academic hospital, scientific organization or investigator. A party that provides funding for a study but does not commission is not regarded as the sponsor, but referred to as a subsidizing party.
SUSAR  Suspected unexpected serious adverse reaction

tPA  Tissue plasminogen activator
**SUMMARY**

**Protocol title:** Direct Intra-arterial thrombectomy in order to Revascularize AIS patients with large vessel occlusion Efficiently in Chinese Tertiary hospitals: a Multicenter randomized clinical Trial (DIRECT-MT)

**Rationale:** Intra-arterial treatment (IAT) by means of retrievable stents has been proven safe and effective in patients with acute ischemic stroke with confirmed large vessel occlusion of the anterior circulation and in whom the procedure can be started within 6 hours from onset. Despite recanalization, a considerable proportion of patients do not recover. This can be attributed to potential adverse effects of the intravenous treatment (IVT) prior to IAT. These effects could include neurotoxicity, blood brain barrier leakage and thrombus fragmentation through softening of the thrombus.

Another reason for non-recovery in MRCLEAN was the occurrence of symptomatic intracranial hemorrhage (sICH) in 7% of patients, which was fatal in 65%. sICH occurred as often in the intervention as in the control group, suggesting that this complication could not be attributed to the IAT, but rather to pre-treatment with IVT. The HERMES study showed that the incidence of symptomatic intracranial hemorrhage was about 4.4% in the western population. Considering the high rate of intracranial atherosclerosis in Chinese population, the clinical prognosis after thrombectomy may be slightly better. Therefore, we hypothesize that direct IAT may lead to a 4% absolute increase in good outcome compared to IAT preceded by IVT.

**Objective:** To assess the effect of direct IAT compared to IVT followed by IAT, in patients with acute ischemic stroke, caused by a CTA-confirmed occlusion of the anterior circulation (intracranial segment of ICA, M1, proximal M2) on functional outcome.

**Study design:** This is a parallel group, randomized clinical trial of direct IAT versus IVT with IAT. The trial has observer blind assessment of the primary outcome and of neuro-imaging at baseline and follow up.

**Study population:** Patients with acute ischemic stroke and a confirmed anterior circulation occlusion by CTA. Initiation of IVT must be feasible within 4.5 hours from symptom onset. Age must be 18 or over and NIHSS 2 or more.

**INCLUSION CRITERIA**

- a clinical diagnosis of acute ischemic stroke,
- caused by a large vessel occlusion of the anterior circulation (intracranial segment of ICA or middle M1/proximal M2) cerebral artery confirmed by CTA,
- CT or MRI ruling out intracranial hemorrhage,
- eligible for IVT and IAT (within 4.5 hours after symptom onset),
- a score of at least 2 on the NIH Stroke Scale,
- age of 18 years or older,
- written informed consent.
EXCLUSION CRITERIA

- Pre-stroke disability which interferes with the assessment of functional outcome at 90 days, i.e. mRS >2
- Any contra-indication for IVT, according to guidelines of the American Heart Association, i.e.:
  - arterial blood pressure exceeding 185/110 mmHg
  - blood glucose less than 2.7 or over 22.2 mmol/L
  - cerebral infarction in the previous 6 weeks with residual neurological deficit or signs of recent infarction on neuro-imaging
  - serious head trauma in the previous 3 months
  - major surgery or serious trauma in the previous 2 weeks
  - gastrointestinal or urinary tract hemorrhage in the previous 3 weeks
  - previous intracerebral hemorrhage
  - use of anticoagulant with INR exceeding 1.7
  - known thrombocyte count less than $100 \times 10^9$/L
  - treatment with direct thrombin or factor X inhibitors
  - treatment with heparin (APTT exceeds the upper limit of normal value) in the previous 48 hours.

**Intervention:** The intervention group will undergo immediate IAT using a stent retriever, as recommended by the steering committee. The standard care group will receive IVT 0.9 mg/kg with a maximum dose of 90 mg in one hour, followed by IAT using a stent retriever. We strive to reduce delays associated with IVT administration to a minimum to adequately assess the effect of IVT itself with IAT.

**Main study parameters/outcomes:** The primary effect parameter will be the common odds ratio, estimated with ordinal logistic regression, which represents the shift on the full distribution of the modified Rankin Scale at 3 months. The estimate will be adjusted for the known prognostic variables age, pre-stroke mRS, time from onset to randomization, stroke severity (NIHSS) and collaterals and adjusted and unadjusted estimates with corresponding 95% confidence intervals will be reported.

Secondary outcomes include mortality at 90 days, stroke severity at $24 \pm 6$ hours and 5-7 days, recanalization on CTA at 24-72 hours, dichotomous clinical outcome on the mRS and infarct size at 5-7 days. Safety outcomes include rate of sICH.
1. Introduction and rationale

Stroke is a major cause of death and disability. The latest National Epidemiological Survey of Stroke in China \(^1\) (Ness-China) showed that: the standardized prevalence, incidence and mortality of stroke in China in 2013 were 1114.8/100 thousand person/year, 246.8/100 thousand person/year and 114.8/100 thousand person/year respectively. In 1985, the prevalence of stroke in China was only 365/100 thousand person/year \(^2\). In the case of a gradual decline in the incidence and mortality of stroke in European and American countries, the incidence of Chinese people gradually increased at a rate of 8.7% per year, which was significantly higher than the overall annual incidence of stroke in the world \(^3\)-\(^5\).

Early 2015, the outlook of acute stroke changed dramatically over the course of a few months. It was shown that patients with acute ischemic stroke (AIS) caused by a large vessel occlusion of the anterior circulation benefit from intra-arterial treatment (IAT). IAT using a stent retriever leads to an absolute increase in good functional outcome in 15% to 25% of patients treated within 6 hours. This was first reported in the MR CLEAN trial and later confirmed in 4 other trials \(^6\)-\(^10\).

In randomized trials of acute ischemic stroke, intravenous thrombolysis (IVT) with alteplase strongly reduced the risk of a poor outcome \(^11\),\(^12\). However, two thirds of the patients treated with IVT within 3 hours of stroke onset in these trials were dead or dependent at the end of follow-up. In the MR CLEAN trial, 67% of the patients in the endovascular treatment group were dead or dependent at three months. The high risk of a poor outcome, even after these acute revascularization strategies, may to a large extent be explained by no-reflow. No-reflow has been linked to distal micro vascular damage or dysfunction as a result of tissue necrosis and cell death, or the intervention simply being late.

Currently the role of IVT in acute ischemic stroke treatment with IAT is unclear. The incidence of bleeding complications was similar in MR CLEAN to the frequency in the NINDS IVT trial and SITS MOST registry \(^13\),\(^14\). In MR CLEAN, the occurrence of symptomatic intracranial hemorrhage (sICH) (7%, fatal in 65%) was similar between the intervention and the control group, suggesting that this complication could not be attributed to the IAT, but rather to pre-treatment with IVT. According to the meta-analysis of the five RCT results, the incidence of symptomatic intracranial hemorrhage in westerners was 4.4%. However, there are differences in the pathogenesis of stroke between eastern and western populations. In 2017, a retrospective ACTUAL study based on Chinese population showed that 44.3% acute intracranial artery occlusion is caused by atherosclerosis, which was significantly higher than westerners. At the same time, there was no significant difference in the incidence of sICH between direct endovascular treatment group and bridging treatment group. This may remind us that the increased proportion of acute intracranial atherosclerotic occlusion did not significantly influence the incidence of sICH. Whether the increase of the stent implantation proportion will affect clinical outcome is unknown. In the ACTUAL study, the incidence of aICH in the intravascular treatment group was significantly lower than that in the bridging treatment group (28.3% vs. 44.9%, \(P=0.01\)). whether the increase in the proportion of stent implantation will increase the incidence of ICH after IVT, which are currently unknown and need to be studied.

According to the above comprehensive analysis, we hypothesize that direct IAT, without pretreatment with IVT, in selected patients may lead to a 4% absolute increase in good outcome.
because of a reduction in the occurrence of sICH and an increase in treatment effect of IAT.

MR CLEAN is the earliest and only completed RCT study on the evaluation of the efficacy of IAT. This study intends to conduct in-depth cooperation with MR CLEAN study team in the Netherlands, and conducts an international prospective multi-center randomized controlled study in both locations to explore the differences in the clinical outcome between the two to answer the concept whether the clinical outcome of this direct IAT is better than that of the current treatment by comparing direct IAT with IVT and IAT bridging treatments, and the efficacy of stents in different populations (12).

2. Study objectives

The primary objective of this trial is to assess the effect of direct IAT compared with IVT followed by IAT, on functional outcome in patients with AIS, caused by an anterior circulation occlusion that is confirmed by CTA.

The secondary objective is to explore for superiority of direct IAT relative to IVT followed by IAT.

The tertiary objective is to assess the effect of direct IAT compared with IVT with IAT on neurological recovery (NIHSS), infarct size and occurrence of sICH.

The fourth objective is to collect thrombi and to analyze them with respect to their potential for treatment effect modification.

3. Study design

This is a multicenter phase IV prospective randomized clinical trial with open-label treatment and blinded outcome assessment (PROBE). The study will run for 4 years in intervention centers.

4. Study population

4.1. Population (Base)

The latest National Epidemiological Survey of Stroke in China (1) (Ness-China) showed that: the standardized prevalence, incidence and mortality of stroke in China in 2013 were 1114.8/100 thousand person/year, 246.8/100 thousand person/year and 114.8/100 thousand person/year respectively. In 1985, the prevalence of stroke in China was only 365/100 thousand person/year (2). In the case of a gradual decline in the incidence and mortality of stroke in European and American countries, the incidence of Chinese people gradually increased at a rate of 8.7% per year, which was significantly higher than the overall annual incidence of stroke in the world (3-5).

4.2. Participating centers and center eligibility

To be fully eligible for participation in the trial and to include patients in the trial, centers should meet the following minimum criteria:

- Local tertiary hospitals;
- Centers with experience in conducting acute stroke trials;

Version No.: 3.0; Date: August 20, 2019
○ It can simultaneously perform intravenous thrombolysis and endovascular thrombectomy, and completes more than 30 endovascular treatment of acute ischemic stroke each year,

○ The intervention team should have experience with endovascular interventions for cerebrovascular disease (IAT, carotid stenting or aneurysm coiling), peripheral artery disease, or coronary artery disease, and the stroke team (which includes neurologists and interventionists) should have previous experience with intra-arterial treatment,

○ The intervention team should make use of one or more of the devices that have been approved by CFDA. Use of other devices is not allowed in the trial.

○ At least one member of the intervention team should have previous experience with the particular device.

Note: Patients may only be included in the trial when the intervention team that will actually treat the patient includes at least one interventionist with previous experience with IAT.

4.3. Inclusion criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

– a clinical diagnosis of acute ischemic stroke;
– caused by a large vessel occlusion of the anterior circulation (distal intracranial carotid artery or middle M1/proximal M2) cerebral artery confirmed by CTA;
– CT or MRI ruling out intracranial hemorrhage;
– eligible for IVT and IAT (within 4.5 hours after symptom onset);
– NIHSS ≥ 2;
– age of 18 years or older;
– written informed consent.

4.4. Exclusion criteria

A potential subject who meets any of the following criteria will be excluded from participation in this study:

– Pre-stroke disability which interferes with the assessment of functional outcome at 90 days, i.e. mRS >2;
– Any contra-indication for IVT, according to guidelines of the American Heart Association (27), i.e.:
  ○ blood pressure > 185/110 mmHg,
  ○ blood glucose < 2.7 or > 22.2 mmol/L,
  ○ cerebral infarction in the previous 6 weeks with residual neurological deficit or signs of
recent infarction on neuro-imaging,
  ○ serious head trauma in the previous 3 months,
  ○ major surgery or serious trauma in the previous 2 weeks,
  ○ gastrointestinal or urinary tract hemorrhage in the previous 3 weeks,
  ○ previous intracerebral hemorrhage,
  ○ use of anticoagulant with INR exceeding 1.7,
  ○ known thrombocyte count less than $100 \times 10^9$/L
  ○ treatment with direct thrombin or factor X inhibitors,
  ○ treatment with heparin (APTT exceeds the upper limit of normal value) in the previous 48 hours.

4.5. Sample size calculation

We based our estimations on the distribution of the modified Rankin Scale (mRS) in the control group of the trial, which we derived from the intervention group of the MR CLEAN trial \(^{(9)}\): mRS 0: 3%; mRS 1: 9%; mRS 2: 21%; mRS 3: 18%; mRS 4: 22%; mRS 5: 6% and mRS 6: 21%. We assumed a favorable treatment effect with a common odds ratio (cOR) of 1.163, corresponding to a 4% absolute increase in the rate of mRS scores of 0-2. The main purpose is to demonstrate non-inferiority, that is, the lower limit of the 95% confidence interval does not cross the pre-specified cOR non-inferiority Cutoff of 0.8. In a simulation with 5000 runs we computed the proportion of positive trials, for a given sample size. A sample size of 710 was determined to detect the pre-defined non-inferiority with a power of 80% and two-sided alpha of 0.05. Using covariate adjustment with at most 25%, a conservative 15% sample size reduction can be achieved, plus 5% dropout rate, leading to a final sample size of 636, 318 per arm.

5. Treatment of subjects

5.1. Investigational treatment

Patients in the control group will receive IVT (alteplase) according to the guidelines of the American Heart Association. \(^{(27)}\) Patients in the intervention group will not receive this treatment (nor placebo) and proceed directly with IAT. Patients in both groups will undergo IAT. Please note that to assess the effect of IVT itself and not the applied treatment strategy, we strive to reduce delays in the control group due to IVT administration to an absolute minimum. Remaining differences between treatment groups in time from randomization to groin puncture will be recorded. All stent retriever devices for IAT, which are approved by CFDA for this purpose, are allowed in the trial as a first line of defense.

Other mechanical devices (aspiration devices) are allowed as a second option, when the first device has failed according to the interventionist, usually after 3 passes. The further choice of the particular device for a certain patient is left to the discretion of the interventionist.
The target time from study randomization to groin puncture will be as fast as possible. All patients must undergo groin puncture within a median of 60 minutes after randomization.

5.2. Use of co-intervention

No standard co-medication is advised by the steering committee. Antiplatelet or antithrombotic treatment will generally be started at 24 hours after the intervention, according to national protocols.

5.3. Escape medication

If deemed by the interventionist, local application (intra-arterial) of alteplase is allowed in any of the patients included in the DIRECT-MT. Patients in the direct IAT group in whom good recanalization (eTICI 2b-3) was not reached, may be treated afterwards with 0.9 mg/kg IVT if the 4.5 hour window or maximum dose is not exceeded. Patients who have been pre-treated with i.v. alteplase should not receive more than 30mg alteplase during intra-arterial treatment. The steering committee recommends that the alteplase is delivered in shots of 5 mg in 5-10 minute intervals.

In individual cases, an equivalent dose of 400,000 U urokinase, delivered in shots of 50.000 - 100.000 U, in 5-10 minutes time intervals, is also accepted as escape medication.

Vessel patency should be checked after each shot.

6. Investigational product

6.1. Name and description of investigational product

The comparator in this trial is IVT with alteplase (actilyse). The intervention is omitting IVT before IAT.

6.2. Summary of findings from clinical studies

The value of IVT in patients with AIS has been determined in multiple RCTs with a potential treatment window up to 4.5 hours after symptom onset\(^\text{30, 31}\). It has been a standard care for several years. All trials investigating the benefit of IAT in AIS had a control group consisting of patients receiving usual care\(^\text{6-9, 32}\). This meant that few patients were treated directly, without prior IVT. In MR CLEAN, this concerned only 55 patients (11%). Subgroup analysis showed a similar effect size in patients not treated with IVT (OR = 2.06 [95% Confidence Interval (CI): 0.69-6.13]) as in patients pretreated with IVT (OR =1.71 [95% CI: 1.22-2.40]).\(^\text{9}\) REVASCAT showed comparable results: 56 patients not treated with IVT (OR = 2.6 [95% CI: 1.0-7.1]) as to 76 patients who were pretreated (OR = 1.4 [95% CI: 0.8-2.6]).\(^\text{7}\) Moreover, in ESCAPE, patients without IV pretreatment seemed to benefit (OR = 2.6 [95% CI: 1.1-5.9]) from endovascular treatment.\(^\text{6}\) When we combined the published data there is no heterogeneity (p= 0.78). In a fixed effect model, the effect estimate is quite precise and statistically significant (OR = 2.3 [95% CI: 1.5-3.7]). We believe that the data from these three randomized controlled trials show that patients not pretreated with IVT may benefit from intervention.

6.3. Summary of known and potential risks and benefits
For known possible undesirable effects of actilyse, see the summary of product characteristics supplied.

6.4. Description and justification of route of administration and dosage

The route and dosage of administration are based on the American Heart Association guidelines.

7. Non-investigational product

7.1. Name and description of non-investigational products

Stent-retrievers for IAT are the background treatment in this trial. The devices approved by CFDA during the research may be used as primary device for IAT (not limited to the table listed below)

<table>
<thead>
<tr>
<th>Device name</th>
<th>Manufacturer</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solitaire</td>
<td>Medtronic / Covidien</td>
<td>Retrievable stent</td>
</tr>
<tr>
<td>Trevo</td>
<td>Stryker</td>
<td>Retrievable stent</td>
</tr>
<tr>
<td>Revive</td>
<td>Johnson &amp; Johnson / Cerenovus</td>
<td>Retrievable stent</td>
</tr>
</tbody>
</table>

7.2. Summary of findings from clinical studies

Seven randomized clinical trials that predominantly used stent thrombectomy have been carried out. All trials showed a beneficial effect of intervention compared to usual care, which most often included treatment with iv-alteplase. The effect size ranged from 11 to approximately 25% increase in proportion of non-disabled patients at 3 months after randomization. As stated in paragraph 7.3, the subgroup analyses of recent trials suggest that patients not pretreated with IVT may benefit from intervention.

7.3. Summary of known and potential risks and benefits

The potential benefits of the intervention have been described in 3.3. The potential risks consist of intracranial and extracranial hemorrhage and hemorrhagic infarction, procedure related risks such as dissection, perforation and infarctions in other vascular territories, and postprocedural events such as infections. In the 5 trials, the risks of hemorrhage and hemorrhagic infarction were equal for both the intervention group as the control group. Postprocedural events such as pneumonia and other infections occurred in similar frequencies in both groups, and procedure-related events were infrequent.

8. Method

8.1. Study outcomes

8.1.1. Main study outcome

The primary outcome is the score on the modified Rankin Scale (Table 1 in Appendix) at 90 days (± 14 days). The mRS is the preferred disability parameter for clinical trials in stroke. The mRS is an
ordinal hierarchical scale incorporating six categories from 0 up to and including 5, and describes the range of disability encountered post stroke. ‘Death’ is assigned a score of 6. Assessment of outcome on the mRS will be performed by independent assessors, blinded to the allocated and actually received treatment. Their assessment will be based on standardized reports of a telephone interview by trained research personnel who are not aware of treatment allocation.

8.1.2. Secondary outcomes

Secondary outcomes are the following:

- Death within 90 days (± 14 days)
- Pre-interventional recanalization
- eTICI score on final angiography of IAT. (36) (Table 2 in Appendix)
- Recanalization rate at 24-72 hours, assessed with CTA
- Score on the NIHSS at 24 ± 6 hours and 5-7 days. (37) (Table 3 in Appendix)
- Final infarct volume at 5-7 days. Final infarct volume will be assessed with the use of an automated, validated algorithm. (38) Infarct size at day 5-7 will be compared with plain CT and perfusion CT results (if available) at baseline.
- Dichotomized mRS of 0-1 vs. 2-6 at 90 days (± 14 days)
- Dichotomized mRS of 0-2 vs. 3-6 at 90 days (± 14 days)
- Dichotomized mRS of 0-3 vs. 4-6 at 90 days (± 14 days)
- Score on the EQ5D-5L and Barthel index at 90 days (± 14 days) (39) (40)

8.1.3. Safety outcomes

- Hemorrhages according to the Heidelberg criteria (40)
- sICH scored according to the Heidelberg criteria (41)
- Embolization in new territory on angiography during IAT
- Occurrence of aneurysma spurium
- Occurrence of groin hematoma
- Infarction in new territory at 5-7 days (42) (Table 8 in Appendix)
- Death from all causes within 90 days (± 14 days)

8.1.4. Other study parameters

Baseline parameters that will be recorded include age; sex; previous stroke; conditions such as hypertension, diabetes mellitus, atrial fibrillation, myocardial infarction; smoking status; medication including antiplatelet agents and anticoagulants; vital parameters such as blood pressure, body temperature; weight and height; neurological examinations including NIHSS; laboratory examination
including INR, APTT, PLT, glucose, creatinine; and imaging results on admission (e.g. clot burden score, table 6 in Appendix).

We will record the actually received dose, type and timing of iv thrombolytic medication.

Additionally, we will record time from onset to ER, CT, randomization, start of IAT, first reperfusion and end of procedure. The devices and the order in which they are used will be recorded, and the type of anesthesia (if any) and sedation will be noted.

8.2. Randomization, blinding and treatment allocation

The randomization procedure will be computer and web-based. Randomization is allowed when the occlusion has been established by CTA. Randomization will be stratified by center.

It will not be possible to view the treatment allocation before the patient is registered in the study database, nor will it be possible to remove the patient from the study after treatment assignment has become known. Both patient and treating physician will be aware of the treatment assignment. Information on outcome at three months will be assessed through standardized forms and procedures, by a trained investigator blinded for treatment allocation. Interviews will be recorded. Assessors who are blinded to the treatment allocation will perform assessment of outcome on the modified Rankin scale on this information. Results of neuro-imaging will be also assessed in a blinded manner. Information on treatment allocation will be kept separate from the main study database. The steering committee will be kept unaware of the results of interim analyses of efficacy and safety. An independent trial statistician will combine data on treatment allocation with the clinical data in order to report to the data monitoring committee (DSMB).

8.3. Study procedures

All patients will undergo assessment of the NIHSS at baseline, 24±6 hours and 5-7 days, which is routine in clinical procedure. It will be carried out by certified assessors. Patients will undergo NCCT and CTA at baseline. After 24-72 hours CTA is repeated to determine recanalization. At 5-7 days, patients will undergo NCCT to assess infarct size.

In addition, this trial also makes use of “waste material”: retrieved thrombi during intervention. These thromboses will be stored in the participating study centers for follow-up analysis.

8.4. Withdrawal of individual subjects

Subjects can leave the study at any time for any reason if they wish to do so without any consequences. The investigator can decide to withdraw a subject from the study for urgent medical reasons. The data from subjects who do not provide consent will be treated anonymously, and used for baseline analysis to further describe this population. At the time of analysis, missing data are interpolated, including the final mRS score. The key part of personal data will be cleared.

8.5. Premature termination of the study

The study will only be terminated prematurely if the Data Safety Monitoring Board recommends
stopping. In case of premature termination of the study, the database will be closed after 90 days assessment of the last enrolled patient and results will be reported.

9. Safety reporting

9.1. Temporary halt for reasons of subject safety

The sponsor will suspend the study if there is sufficient ground that continuation of the study will jeopardize subject health or safety. The sponsor will notify the undue delay caused by temporary halt as well as the reason for such an action. The study will be suspended pending further review by the EC. The investigator should ensure that all subjects are kept informed.

9.2. AEs, SAEs and SUSARs

9.2.1. Adverse events (AEs)

Adverse events are defined as any undesirable experience occurring to a subject during the study, whether or not considered related to trial procedure. All adverse events reported spontaneously by the subject or observed by the investigator or his staff will be recorded.

9.2.2. Serious adverse events (SAEs)

A serious adverse event is any unfavourable medical occurrence or effect as follows

- Results in death;
- Life threatening (at the time of the event);
- Require inpatient hospitalization or prolongation of existing inpatients' hospitalization.
- congenital anomaly or birth defect;
- results in persistent or significant disability or incapacity;
- that required medical or surgical intervention to preclude of;

Any other important medical event that did not result in any of the outcomes listed above due to medical or surgical intervention but could have been based upon appropriate medical judgment.

An elective hospital admission will not be considered as a serious adverse event. Technical complications or vascular damage at the target lesion such as perforation or dissection that do not lead to clinically detectable SAE and neurological deterioration not caused by intracranial hemorrhage, new ischemic stroke, but are considered as consistent with the natural course of the ischemic stroke and its treatment, will not be reported immediately.

Serious adverse events will be immediately, after coming to notice of the investigator, reported to the site EC and sponsor.

The investigator will report the following SAEs occurring in the study period to the sponsor without
undue delay of obtaining knowledge of the events: Death from any cause; symptomatic intracranial hemorrhage scored, extracranial hemorrhage, aspiration pneumonia, allergic contrast reactions, new ischemic stroke in different vascular territory.

SAEs of this study are reported using the "Suspicious Medical Device Adverse Event Report Form" (Table 9 in the appendix).

9.3. Follow-up of adverse events

All AEs will be followed until they have abated, or until a stable situation has been reached.

Depending on the event, follow up may require additional tests or medical procedures as indicated, and/or referral to the general physician or a medical specialist.

SAEs need to be reported till the end of the study in China, as defined in the protocol.

9.4. Data Safety Monitoring Board (DSMB)

In order to increase the safety of the intervention, the trial will be monitored by an independent DSMB. The DSMB will be chaired by a neurologist, and include a neuro-interventionist and an independent methodologist/statistician. The DSMB plans to conduct two interim analyses to evaluate the treatment effect and the incidence of adverse reactions according to the procedure at the end of the 90-day follow-up of 1/3 and 2/3 subjects, respectively. During the period of patient enrollment into the study, interim analyses of mortality and of any other information that is available on major outcomes (including serious adverse events believed to be due to treatment) will be supplied, in strict confidence, to the chairman of the DSMB, along with any other analyses that the DSMB may request. In the light of these analyses, DSMB will advise the chairman of the Steering Committee if, in their view, the randomized comparisons in DIRECT-MT have provided both (i) "proof beyond reasonable doubt" that for all, or for some specific types of patients, one particular treatment is clearly indicated or clearly contraindicated in terms of a net difference in outcome, and (ii) evidence that might reasonably be expected to materially influence patient management. Appropriate criteria of proof beyond reasonable doubt cannot be specified precisely, but a difference of at least 3 standard deviations in an interim analysis of a major outcome may be needed to justify halting, or modifying, the study prematurely. This criterion has the practical advantage that the number of interim analyses is of little importance.

The advice(s) of the DSMB will be sent to the sponsor of the study by the chair of the steering committee. Should the sponsor decide not to fully implement the advice of the DSMB, the sponsor will send the advice to the EC, including a note to substantiate why (part of) the advice of the DSMB will not be followed.

10. Statistical analysis

10.1. Statistical analysis

The primary effect parameter will be the common odds ratio, estimated with ordinal logistic regression, which represents the shift on the 7-category mRS scale measured at 3 months. The estimate will be adjusted for the known prognostic variables age, pre-stroke mRS, time from onset
to randomization, stroke severity (NIHSS) and collaterals and adjusted and unadjusted estimates with corresponding 95% confidence intervals will be reported. To explore for non-inferiority, we will analyze whether the lower bound of the 95% CI crossed 0.8, our pre-specified non-inferiority margin.

If applicable, the secondary outcomes will be analyzed using linear, logistic, or ordered regression analysis method, with the same correction method as the primary outcomes.

All analyses will be performed according to the intention-to-treat principle. Baseline data by treatment allocation will be reported with statistical procedures. Missing values for baseline characteristics will be reported. Missing baseline characteristics will be imputed using regression imputation. Pre-defined subgroups will be analyzed by testing for interaction between the specific baseline characteristic and treatment.

10.2. Subgroup analysis

The effect of intervention on the modified Rankin Scale will be analyzed in subgroups determined by the following variables:

- Tertiles of time from onset of symptoms to randomization, groin puncture and revascularization
- Ipsilateral extracranial carotid tandem lesion
- Occlusion location
- Collateral grades 0 to 3 as defined by Tan et al. (43) (Table 7 in Appendix)
- Thrombus characteristics (thrombus perviousness (44), clot burden, density)
- Large vessel occlusion due to different etiologies

10.3. Interim analysis

See Paragraph 9.4.

11. Ethical considerations

11.1. Regulation statement

The study will be conducted according to the principles of the Declaration of Helsinki (October 2013) (45)

11.2. Recruitment and consent

Following Article 21 of "Standard for quality management of medical device clinical trials" (June 1, 2016)¹, the investigators should adequately explain the details of the clinical trial, including known, foreseeable risks and possible adverse event, etc., to the subject or to the guardians of subjects.

¹ http://www.sda.gov.cn/WS01/CL1101/148101.html

Version No.: 3.0; Date: August 20, 2019
11.3. Problems of minors or incapacitated subjects

Minors (under 18 years old) will not be included in this trial. In the trial, about 50% of patients have language defects due to stroke, and about a quarter of the patients may suffer from a certain degree of lack of sense of disease. In such case, following the first paragraph of Article 23 of "Standard for quality management of medical device clinical trials" (June 1, 2016), for incapacitated subjects, if the ethics committee agrees in principle, and investigators believe that subjects participating in clinical trials are in their own interest, they can also enter the clinical trial, but their guardians should sign the name and date before the trial.

11.4. Benefits and risks assessment, group relatedness

The expected benefit from direct intra-arterial treatment compared to IVT followed by IAT may amount to 4% absolute increase in independent living at 3 months. Patients who have been allocated to the control group will be given usual treatment according to international, national and local guidelines. This includes treatment with IVT, followed by IAT.

11.5. Compensation for injury

Each participating center has purchased liability insurance. This insurance provides cover for damage to research subjects through injury or death caused by the study.

12. Administrative aspects, monitoring and publication

12.1. Handling and storage of data and documents

All data will be entered into a web-based database (EDC) by local research personnel. Subject records are coded by a unique study number. The local investigators will keep a list showing codes and names. Unique documents with identifying information will be stored separately from the study database in digital files, categorized by study number on a secure drive system, only accessible to the study coordinator.

12.2. Monitoring and quality assurance

The monitors will arrange visits according to the speed of enrollment of each center and the deviations found in the past. In principle, the inspection visit will be arranged within 5 working days of the center enrollment. The monitor will validate informed consent and source data for all subjects. The monitoring data including but not limited to: in-patient medical records, outpatient medical records, follow-up medical records, imaging materials and evaluation forms, etc. At the same time, the monitor will check the integrity and consistency of EDC data entry.
12.3. Amendment

Amendments are changes made to the research protocol after a favorable opinion by EC has been given. All amendments will be notified to the EC that gave a favorable opinion.

12.4. Annual progress report

The sponsor/investigator will submit a summary of the progress of the trial to the EC once a year. Information should be provided: the date of inclusion of the first subject, numbers of subjects included and numbers of subjects that have completed the trial, serious adverse events/serious adverse reactions, other problems and amendments.

12.5. Temporary halt and (prematurely) end of study report

The investigator/sponsor will notify the EC of the end of the study within a period of 8 weeks. The end of the study is defined as the last patient’s last visit.

The sponsor will notify the EC immediately of a temporary halt of the study, including the reason of such an action.

In case the study is ended prematurely, the sponsor will notify the EC within 15 days, including the reasons for the premature termination.

Within one year after the end of the study, the investigator/sponsor will submit a final study report with the results of the study, including any publications/abstracts of the study, to the EC and the Competent Authority.

The insurance applies to the damage that becomes apparent during the study or within 4 years after the end of the study.

12.6. Public disclosure and publication policy

The trial has been registered in clinicaltrials.gov. Clinicaltrials: NCT03469206

The study database will be closed within one month after the last scheduled follow-up date of the last included patient. A manuscript which at least describes the study and the answer to the primary research question will be submitted to a major clinical journal within 3 months from closure of the database. The manuscript will be shared with the financial sponsor(s) one month before submission, but the financial sponsor(s) will have no influence on its contents.

Anonymous data can be requested from the PI with a detailed description containing the aims and methods of the study for which the data are intended to be used. Data will be made available for this purpose at least 18 months after publication of the main report. Data may also be shared with non-commercial parties for scientific purposes, including individual patient meta-analyses, and with commercial parties for regulatory purposes.

These purposes should be specified in the informed consent form.
13. References


The modified Rankin Scale (mRS) is an ordinal hierarchical scale ranging from 0 to 5, with higher scores indicating more severe disability. A score of 6 has been added to signify death.

<table>
<thead>
<tr>
<th>Category</th>
<th>Short description</th>
<th>Long description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No symptoms</td>
<td>No symptoms</td>
</tr>
<tr>
<td>1</td>
<td>Symptoms, no disability</td>
<td>Minor symptoms that do not interfere with lifestyle</td>
</tr>
<tr>
<td>2</td>
<td>Slight disability</td>
<td>Slight disability, symptoms that lead to some restriction in lifestyle, but do not interfere with the patient's capacity to look after himself.</td>
</tr>
<tr>
<td>3</td>
<td>Moderate disability</td>
<td>Moderate disability, symptoms that significantly restrict lifestyle and prevent totally independent existence</td>
</tr>
<tr>
<td>4</td>
<td>Moderately severe disability</td>
<td>Moderately severe disability, symptoms that clearly prevent independent existence though not needing constant attention</td>
</tr>
<tr>
<td>5</td>
<td>Severe disability</td>
<td>Severe disability, totally dependent patient requiring constant attention day and night.</td>
</tr>
<tr>
<td>6</td>
<td>Death</td>
<td>Death</td>
</tr>
</tbody>
</table>
Table 2  Extended Treatment In Cerebral Ischemia (Etici) Scale \(^{(36)}\)

<table>
<thead>
<tr>
<th>eTICI grade</th>
<th>Short description</th>
<th>Long description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No perfusion</td>
<td>No antegrade flow beyond the point of occlusion</td>
</tr>
<tr>
<td>1</td>
<td>Limited reperfusion</td>
<td>Antegrade reperfusion past the initial occlusion, but limited distal branch filling with little or slow distal reperfusion</td>
</tr>
<tr>
<td>2a</td>
<td>&lt;50% reperfusion</td>
<td>Antegrade reperfusion of less than half of the occluded target artery previously ischemic territory (eg, in 1 major division of the MCA and its territory)</td>
</tr>
<tr>
<td>2b</td>
<td>≥50% and &lt;90% reperfusion</td>
<td>Antegrade reperfusion of more than half of the previously occluded target artery ischemic territory (eg, in 2 major divisions of the MCA and its territories)</td>
</tr>
<tr>
<td>2c</td>
<td>≥90% reperfusion</td>
<td>Near complete antegrade reperfusion of the previously occluded target artery ischemic territory, except for slow flow or distal emboli in a few distal cortical vessels</td>
</tr>
<tr>
<td>3</td>
<td>100% reperfusion</td>
<td>Complete antegrade reperfusion of the previously occluded target artery ischemic territory, with absence of visualized occlusion in all distal branches</td>
</tr>
</tbody>
</table>

MCA: middle cerebral artery; eTICI; extended treatment in cerebral ischemia scale
**Table 3  NIH Stroke Scale**

The NIHSS is an ordinal hierarchical scale to evaluate the severity of stroke by assessing a patient’s performance. (23) Scores range from 0 to 42, with higher scores indicating a more severe deficit. Administer stroke scale items in the order listed. Record performance in each category after each subscale exam. Do not go back and change scores. Follow directions provided for each exam technique. Scores should reflect what the patient does, not what the clinician thinks the patient can do. The clinician should record answers while administering the exam and work quickly. Except where indicated, the patient should not be coached (i.e. repeated requests to patient to make a special effort).

<table>
<thead>
<tr>
<th>Instructions</th>
<th>Scale definition</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1a. Level of consciousness.</strong> The investigator must choose a response if a full evaluation is prevented by such obstacles as an endotracheal tube, language barrier, orotracheal trauma/bandages. A 3 is scored only if the patient makes no movement (other than reflexive posturing) in response to noxious stimulation.</td>
<td>0 = <strong>Alert;</strong> keenly responsive. 1 = <strong>Not alert;</strong> but arousable by minor stimulation to obey, answer, or respond. 2 = <strong>Not alert;</strong> required repeated stimulation to attend, or is obtunded and requires strong or painful stimulation to make movements (not stereotyped). 3 = Responds only with reflex motor or autonomic effects or totally unresponsive, flaccid and areflexic.</td>
</tr>
<tr>
<td><strong>1b. LOC Questions:</strong> The patient is asked the month and his/her age. The answer must be correct – there is not partial credit for being close. Phasic and stuporous patients who do not comprehend the questions will score 2. Patients unable to speak because of endotracheal intubation, orotracheal trauma, severe dysarthria from any cause, language barrier, or any other problem not secondary to aphasia are given a 1. It is important that only the initial answer be graded and that the examiners not “help” the patient with verbal or non-verbal clues.</td>
<td>0 = Answers both questions correctly. 1 = Answers one question correctly. 2 = Answers neither question correctly.</td>
</tr>
<tr>
<td><strong>1c. LOC Commands:</strong> The patient is asked to open and close the eyes and then to grip and release the non-paretic hand. Substitute another one step command if the hand cannot be used. Credit is given if an unequivocal attempt is made but not completed due to weakness. If the patient does not respond to command, the task should be demonstrated to him or her (pantomime), and the result scored (i.e. follows none, one or two commands). Patients with trauma, amputation, or other physical impediments should be given suitable one-step commands. Only the first attempt is scored.</td>
<td>0 = Performs both tasks correctly. 1 = Performs one task correctly. 2 = Performs neither task correctly.</td>
</tr>
<tr>
<td><strong>2. Best Gaze:</strong> Only horizontal eye movements will be tested. Voluntary or reflexive (oculocephalic) eye movements will be scored, but caloric testing is not done. If the patient has</td>
<td>0= <strong>Normal.</strong> 1= <strong>Partial gaze palsy;</strong> gaze is abnormal in one or both eyes, but forced deviation or total gaze paresis is not present.</td>
</tr>
</tbody>
</table>
a conjugate deviation of the eyes that can be overcome by voluntary or reflexive activity, the score will be a 1. If a patient has an isolated peripheral nerve paresis (CN III, IV or VI), score a 1. Gaze is testable in all aphasic patients. Patients with ocular trauma, bandages, preexisting blindness, or other disorder of visual acuity or fields should be tested with reflexive movements, and a choice made by the investigator. Establishing eye contact and then moving about the patient from side to side will occasionally clarify the presence of a partial gaze palsy.

2= Forced deviation; or total gaze paresis not overcome by the oculocephalic maneuver.

3. Visual: Visual fields (upper and lower quadrants) are tested by confrontation, using finger counting or visual threat, as appropriate. Patients may be encouraged, but if they look at the side of the moving finger appropriately, this can be scored as normal. If there is unilateral blindness or enucleation, visual fields in the remaining eye are scored. Score 1 only if a clear-cut asymmetry, including quadrantanopia, is found. If patient is blind from any cause, score 3. Double simultaneous stimulation is performed in this case. If there is extinction, the patient receives a 1, and the results are used to respond to item 11.

0= No visual loss.
1= Partial hemianopia.
2= Complete hemianopia.
3= Bilateral hemianopia (blind including cortical blindness)

4. Facial palsy: Ask or use pantomime to encourage the patient to show teeth or raise eyebrows and close eyes. Score symmetry of grimace in response to noxious stimuli in the poorly responding or non-comprehending patient. If facial trauma/bandages, orotracheal tube, tape or other physical barriers obscure the face, these should be removed to the extent possible.

0 = Normal symmetrical movements.
1= Minor paralysis (flattened nasolabial fold, asymmetry on smiling)
2= Partial paralysis (total or near-total paralysis of lower face)
3= Complete paralysis of one or both sides (absence of facial movement in the upper and lower face).

5. Motor arm: The limb is placed in the appropriate position: extend the arms (palms down) 90 degrees (if sitting) or 45 degrees (if supine). Drift is scored if the arm falls before 10 seconds. The aphasic patient is encouraged using urgency in the voice and pantomime, but not noxious stimulation. Each limb is tested in turn, beginning with the non-paretic arm. Only in the case of amputation or joint fusion at the shoulder, the examiner should record the score as untestable (UN), and clearly write the explanation for this choice.

0= No drift; limb holds 90 (or 45) degrees for full 10 seconds.
1= Drift; limb holds 90 (or 45) degrees, but drifts down before full 10 seconds; does not hit bed or other support.
2= Some effort against gravity; limb cannot get to or maintain (if cued) 90 (or 45) degrees, drifts down to bed, but has some effort against gravity.
3= No effort against gravity; limb falls.
4= No movement.
UN = Amputation or joint fusion: explain:
5a = Left Arm.
5b = Right arm.

6. Motor leg: The limb is placed in the appropriate position: hold the leg at 30 degrees

0= No drift; leg holds 30-degree position for full 5 seconds.
(always tested supine). Drift is scored if the leg falls before 5 seconds. The aphasic patient is encouraged using urgency in the voice and pantomime, but not noxious stimulation. Each limb is tested in turn, beginning with the non-paretic leg. Only in the case of amputation or joint fusion at the hip, the examiner should record the score as untestable (UN), and clearly write the explanation for this choice.

1= **Drift**; leg falls by the end of the 5-second period but does not hit bed.

2= **Some effort against gravity**; leg falls to bed by 5 seconds, but has some effort against gravity.

3= **No effort against gravity**; leg falls to bed immediately.

4= **No movement**.

UN = Amputation or joint fusion: explain:

6a. Left Leg
6b. Right Leg.

7. **Limb ataxia**: This item is aimed at finding evidence of a unilateral cerebellar lesion. Test with eyes open. In case of visual defect, ensure testing is done in intact visual field. The finger-nose-finger and heel-shin tests are performed on both sides, and ataxia is scored only if present out of proportion to weakness. Ataxia is absent in the patient who cannot understand or is paralyzed. Only in the case of amputation or joint fusion, the examiner should record the score as untestable (UN), and clearly write the explanation for this choice. In case of blindness, test by having the patient touch nose from extended arm position.

0= Absent.
1= **Present in one limb**.
2= **Present in two limbs**.

UN = Amputation or joint fusion: explain:

8. **Sensory**: Sensation or grimace to pinprick when tested, or withdrawal from noxious stimulus in the obtunded or aphasic patient. Only sensory loss attributed to stroke is scored as abnormal and the examiner should test as many body areas (arms [not hands], legs, trunk, face) as needed to accurately check for hemisensory loss. A score of 2, 'severe or total sensory loss', should only be given when a severe or total loss of sensation can be clearly demonstrated. Stuporous and aphasis patients will, therefore, probably score 1 or 0. The patient with brainstem stroke who has bilateral loss of sensation is scored 2. If the patient does not respond and is quadriplegic, score 2. Patients in a coma (item 1a=3) are automatically given a 2 on this item.

0= **Normal**; no sensory loss.
1= **Mild-to-moderate sensory loss**; patients feels pinprick is less sharp or is dull on the affected side; or there is a loss of superficial pain with pinprick, but patient is aware of being touched.

2= **Severe to total sensory loss**; patient is not aware of being touched in the face, arm and leg.

9. **Best language**: A great deal of information about comprehension will be obtained during the preceding sections of the examination. For this scale item, the patient is asked to describe what is happening in the attached picture, to name the items on the attached naming sheet and to read from the attached list of sentences. Comprehension is judged from responses here, as well as to all of the commands in the preceding general neurological exam. If visual loss interferes with the tests, ask the patient to

0= **No aphasia**; normal
1= **Mild-to-moderate aphasia**; some obvious loss of fluency or facility of comprehension, without significant limitation on ideas expressed or form of expression. Reduction of speech and/or comprehension, however, makes conservation about provided materials difficult or impossible. For example, in conversation about provided materials, examiner can identify picture or naming card content from patient's response.

2= **Severe aphasia**; all communication is through fragmentary expression; great need for inference,
identify objects placed in the hand, repeat, and produce speech. The intubated patient should be asked to write. The patient in a coma (item 1a=3) will automatically score 3 on this item. The examiner must choose a score for the patient with stupor or limited cooperation, but a score of 3 should be used only if the patient is mute and follows no one-step commands.

questioning, and guessing by the listener. Range of information that can be exchanged is limited; listener carries burden of communication. Examiner cannot identify materials provided from patient response. 3 = Mute, global aphasia: no usable speech or auditory comprehension.

10. **Dysarthria**: If patient is thought to be normal, an adequate sample of speech must be obtained by asking patient to read or repeat words from the attached list. If the patient has severe aphasia, the clarity of articulation of spontaneous speech can be rated. Only if patient is intubated or has other physical barriers to producing speech, the examiner should record the score as untestable (UN), and clearly write an explanation for this choice. Do not tell the patient why he or she is being tested.

0 = Normal.
1 = Mild-to-moderate dysarthria; patient slurs at least some words and, at worst, can be understood by some difficulty.
2 = Severe dysarthria: patient's speech is so slurred as to be unintelligible in the absence of or out of proportion to any dysphasia, or is mute/anarthric.
UN = Intubated or other physical barrier.

11. **Extinction and Inattention** (formerly Neglect): Sufficient information to identify neglect may be obtained during the prior testing. If the patient has a severe visual loss preventing visual double simultaneous stimulation, and the cutaneous stimuli are normal, the score is normal. If the patient has aphasia but does appear to attend to both sides, the score is normal. The presence of visual spatial neglect or anosagnosia may also be taken as evidence of abnormality. Since the abnormality is scored only if present, the item is never untestable.

0 = No abnormality.
1 = Visual, tactile, auditory, spatial, or personal inattention or extinction to bilateral simultaneous stimulation in one of the sensory modalities.
2 = Profound hemi-inattention or extinction to more than one modality; does not recognize own hand or orients to only one side of space.
Table 4  Barthel Index \(^{(40)}\)

The Barthel index (BI) is an ordinal scale used to measure performance in 10 activities of daily living (ADL). Test scores range from 0 to 100, with higher scores indicating better performance in these activities.

<table>
<thead>
<tr>
<th>Category</th>
<th>Scale definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feeding</td>
<td>0 = unable</td>
</tr>
<tr>
<td></td>
<td>5 = needs help cutting, spreading butter, etc., or requires modified diet</td>
</tr>
<tr>
<td></td>
<td>10 = independent</td>
</tr>
<tr>
<td>Bathing</td>
<td>0 = dependent</td>
</tr>
<tr>
<td></td>
<td>5 = independent (or in shower)</td>
</tr>
<tr>
<td>Grooming</td>
<td>0 = needs to help with personal care</td>
</tr>
<tr>
<td></td>
<td>5 = independent face/hair/teeth/shaving (implements provided)</td>
</tr>
<tr>
<td>Dressing</td>
<td>0 = dependent</td>
</tr>
<tr>
<td></td>
<td>5 = needs help but can do about half unaided</td>
</tr>
<tr>
<td></td>
<td>10 = independent (including buttons, zips, laces, etc.)</td>
</tr>
<tr>
<td>Bowels</td>
<td>0 = incontinent (or needs to be given enemas)</td>
</tr>
<tr>
<td></td>
<td>5 = occasional accident</td>
</tr>
<tr>
<td></td>
<td>10 = continent</td>
</tr>
<tr>
<td>Bladder</td>
<td>0 = incontinent, or catheterized and unable to manage alone</td>
</tr>
<tr>
<td></td>
<td>5 = occasional accident</td>
</tr>
<tr>
<td></td>
<td>10 = continent</td>
</tr>
<tr>
<td>Toilet use</td>
<td>0 = dependent</td>
</tr>
<tr>
<td></td>
<td>5 = needs some help, but can do something alone</td>
</tr>
<tr>
<td></td>
<td>10 = independent (on and off, dressing, wiping)</td>
</tr>
<tr>
<td>Transfers</td>
<td>0 = unable, no sitting balance</td>
</tr>
<tr>
<td>(bed to chair and back)</td>
<td>5 = major help (one or two people, physical), can sit</td>
</tr>
<tr>
<td></td>
<td>10 = minor help (verbal or physical)</td>
</tr>
<tr>
<td></td>
<td>15 = independent</td>
</tr>
<tr>
<td>Mobility (on level surfaces)</td>
<td>0 = immobile or &lt; 50 yards</td>
</tr>
<tr>
<td></td>
<td>5 = wheelchair independent, including corners, &gt; 50 yards</td>
</tr>
<tr>
<td></td>
<td>10 = walks with help of one person (verbal or physical) &gt; 50 yards</td>
</tr>
<tr>
<td></td>
<td>15 = independent (but may use any aid; for example, stick) &gt; 50 yards</td>
</tr>
<tr>
<td>Stairs</td>
<td>0 = unable</td>
</tr>
<tr>
<td></td>
<td>5 = needs help (verbal, physical, carrying aid)</td>
</tr>
<tr>
<td></td>
<td>10 = independent</td>
</tr>
</tbody>
</table>
Guidelines

1. The index should be used as a record of what a patient does, not as a record of what a patient could do.

2. The main aim is to establish degree of independence from any help, physical or verbal, however minor and for whatever reason.

3. The need for supervision renders the patient not independent.

4. A patient's performance should be established using the best available evidence. Asking the patient, friends/relatives and nurses are the usual sources, but direct observation and common sense are also important. However direct testing is not needed.

5. Usually the patient's performance over the preceding 24-48 hours is important, but occasionally longer periods will be relevant.

6. Middle categories imply that the patient supplies over 50 per cent of the effort.

7. Use of aids to be independent is allowed.
Table 5  EUROQOL 5D-5L (39)

The EuroQoL 5-dimensions 5-level (EQ-5D-5L) questionnaire is a standardized measure of health outcome that has been used extensively in patients with stroke.

Under each heading, please tick the ONE box that best describes your health TODAY.

**Mobility**

I have no problems in walking about

I have slight problems in walking about

I have moderate problems in walking about

I have severe problems in walking about

I am unable to walk about

**Self-care**

I have no problems washing or dressing myself

I have slight problems washing or dressing myself

I have moderate problems washing or dressing myself

I have severe problems washing or dressing myself

I am unable to wash or dress myself

**Usual activities (e.g. work, study, housework, family or leisure activities)**

I have no problems doing my usual activities

I have slight problems doing my usual activities

I have moderate problems doing my usual activities

I have severe problems doing my usual activities

I am unable to do my usual activities
Pain/discomfort

I have no pain or discomfort

I have slight pain or discomfort

I have moderate pain or discomfort

I have severe pain or discomfort

I have extreme pain or discomfort

Anxiety/depression

I am not anxious or depressed

I am slightly anxious or depressed

I am moderately anxious or depressed

I am severely anxious or depressed

I am extremely anxious or depressed
Table 6  Clot Burden Score for CTA and MRA *(46)*

<table>
<thead>
<tr>
<th>No contrast agent filling</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supraclinoid internal carotid artery</td>
<td>2</td>
</tr>
<tr>
<td>Proximal M1</td>
<td>2</td>
</tr>
<tr>
<td>Distal M1</td>
<td>2</td>
</tr>
<tr>
<td>Infraclinoid internal carotid artery</td>
<td>1</td>
</tr>
<tr>
<td>A1 branch</td>
<td>1</td>
</tr>
<tr>
<td>M2 branch</td>
<td>1</td>
</tr>
<tr>
<td><strong>Total score: 10 – Sum</strong></td>
<td>Total</td>
</tr>
</tbody>
</table>

Table 7  Collateral Score *(43)*

<table>
<thead>
<tr>
<th>Category</th>
<th>Score</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>0</td>
<td>Absent collaterals</td>
</tr>
<tr>
<td>Poor</td>
<td>1</td>
<td>Collaterals filling ≤50% of the occluded territory</td>
</tr>
<tr>
<td>Intermediate</td>
<td>2</td>
<td>Collaterals filing &gt;50%, but &lt;100% of the occluded territory</td>
</tr>
<tr>
<td>Good</td>
<td>3</td>
<td>Collaterals filling 100% of the occluded territory</td>
</tr>
</tbody>
</table>
### Table 8 Classification of Infarct in a New Territory (42)

<table>
<thead>
<tr>
<th>Classification based on size</th>
<th>Classification based on catheter manipulation across territory ostium</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type I</strong></td>
<td>≤2 mm diffusion lesion (unidentifiable on NCCT)</td>
</tr>
<tr>
<td><strong>Type II</strong></td>
<td>&gt;2 mm to ≤ 20 mm lesion (potentially difficult to identify on CT scan)</td>
</tr>
<tr>
<td><strong>Type III</strong></td>
<td>Large (&gt; 20 mm) infarct</td>
</tr>
<tr>
<td><strong>Type A</strong></td>
<td>Catheter was manipulated past the ostium of the new territory (e.g. large ACA infarct in a patient with an initial M1 occlusion): greater likelihood that infarct is related to the procedure</td>
</tr>
<tr>
<td><strong>Type B</strong></td>
<td>Catheter was not manipulated past the ostium of the new territory (e.g. left PICA infarct in a patient with an initial right M1 occlusion): lower likelihood that infarct is related to procedure</td>
</tr>
</tbody>
</table>

### Report of Suspicious Medical Device Adverse Events

<table>
<thead>
<tr>
<th>A. Patient</th>
<th>C. Medical device</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Name</td>
<td>11. Product name:</td>
</tr>
<tr>
<td>2. Age</td>
<td></td>
</tr>
<tr>
<td>3. Gender:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Male □ Female</td>
</tr>
</tbody>
</table>

| 4. Disease to be treated or expected effect: | 12. Trade name: |

<table>
<thead>
<tr>
<th>B. Overview of adverse event</th>
<th>13. Registration No.:</th>
</tr>
</thead>
<tbody>
<tr>
<td>5. Main conditions of the event:</td>
<td>14. Name of the manufacturer:</td>
</tr>
<tr>
<td></td>
<td>Address of the manufacturer:</td>
</tr>
<tr>
<td></td>
<td>Telephone of the manufacturer:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. Event occurrence date:</th>
<th>15. Model/specification:</th>
</tr>
</thead>
<tbody>
<tr>
<td>7. Time of discovery or knowledge:</td>
<td>Product number:</td>
</tr>
<tr>
<td></td>
<td>Lot number:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>8. Place where the medical device is actually used:</th>
<th>15. Operator:</th>
</tr>
</thead>
<tbody>
<tr>
<td>□ Medical institution □ Home □ Others (please specify):</td>
<td>□ Professional □ Non-professional</td>
</tr>
<tr>
<td></td>
<td>□ Patient □ Others (specific information):</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>9. Consequence</th>
<th>17. Expiration date:</th>
</tr>
</thead>
<tbody>
<tr>
<td>□ Death________________________(specific time);</td>
<td>18. Production date:</td>
</tr>
<tr>
<td>□ Life threatening;</td>
<td>19. Discontinuation date:</td>
</tr>
<tr>
<td>□ Permanent injury to the functional structure of the body;</td>
<td>20. Implantation date (if implanted):</td>
</tr>
<tr>
<td>□ May lead to permanent injury to the functional structure of the body;</td>
<td>21. Preliminary cause analysis of the event:</td>
</tr>
<tr>
<td>□ Need internal and surgical treatment to avoid the</td>
<td></td>
</tr>
</tbody>
</table>

Version No.: 3.0; Date: August 20, 2019
above permanent injury;

- Others (details should be given in "Event description").

10. Event description: (Including at least the device usage time, purpose of use, usage basis, usage situation, adverse event occurred, impact on the victim, treatment measures taken, and the joint use of devices)

22. Preliminary handling of the event:

23. Reporting progress of the event
- User has been notified
- Manufacturer has been notified
- Distributor has been notified
- Pharmaceutical supervision department has been notified

D. Relevance evaluation

1) Was there any reasonable chronological sequence between the using of medical device and occurred/possible injury event? Yes ☐ No ☐

2) Did the occurred/possible injury event belong to the injury type that may be caused by the medical device used? Yes ☐ No ☐ Not clear ☐

3) Could the occurred/possible injury event be explained by combining the effect of drug and/or device, patient's condition or other non-medical device factors? Yes ☐ No ☐ Not clear ☐

Evaluation conclusion: Very likely ☐ Possible ☐ Doubtful ☐ Undeterminable ☐

E. AE assessment

24. Evaluation opinions of provincial monitoring technical site (attached pages are acceptable):

25. Evaluation opinions of national monitoring technical site (attached pages are acceptable):

Reporter: Physician ☐ Technician ☐ Nurse ☐ Others ☐

Signature of reporter: Prepared by China Food and Drug Administration
Figure 1  DIRECT-MT Trial Logo

Figure 2  Patient Flow in the Trial

Patient Flow in the Trial

16. Appendix

16.1 Study committees

<table>
<thead>
<tr>
<th>Steering Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairman: Prof. Liu Jianmin, Changhai Hospital Affiliated to the Second Military Medical University</td>
</tr>
<tr>
<td>Members: Prof. Deng Benqiang, Changhai Hospital Affiliated to the Second Military Medical University; Prof. Charles Majoie, Academisch Medisch Centrum bij de Universiteit van Amsterdam (AMC); and Prof. Yvo Roos, Academisch Medisch Centrum bij de Universiteit van Amsterdam (AMC)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Data Safety Monitoring Board</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairman: Prof. Craig Anderson, The George Institute for Global Health at Peking University Health Science Center</td>
</tr>
<tr>
<td>Members: Prof. Miao Zhongrong, Beijing Tiantan Hospital Affiliated to Capital Medical University; Prof. He Jia, Department of Health Statistics of Second Military Medical University</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Imaging Assessment Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairman: Prof. Jianping Lu, Department of Radiology, Changhai Hospital, Naval Medical University</td>
</tr>
<tr>
<td>Members: Prof. Bing Tian, Department of Radiology, Changhai Hospital, Naval Medical University; Yongxin Zhang, Department of Neurosurgery, Changhai Hospital, Naval Medical University; Lei Zhang, Department of Neurosurgery, Changhai Hospital, Naval Medical University; Hao Wang, Department of Neurology, Linyi People's Hospital; Zhang Shi, Department of Radiology, Changhai Hospital, Naval Medical University; Wenjia Peng, Department of Radiology, Changhai Hospital, Naval Medical University; Xuefeng Zhang, Department of Radiology, Changhai Hospital, Naval Medical University; Xia Tian, Department of Radiology, Changhai Hospital, Naval Medical University; Tengfei Zhou, Department of Radiology, Henan Provincial People's Hospital; Xiaoquan Xu, Department of Radiology, Jiangsu Provincial People's Hospital; Shenqiang Yan, Department of Neurology, Second Affiliated Hospital; Zhejiang University College of Medicine; Jun Ke, Department of Radiology, First Affiliated Hospital, Soochow University; Guang Zhang, Department of Neurosurgery, First Affiliated Hospital, Harbin Medical University; Jun Shi, Core lab, Cardiovascular Chinese research center (CCRC); Fang Li, Core lab, Cardiovascular Chinese research center (CCRC); Xin Wang, Core lab, Cardiovascular Chinese research center (CCRC)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Adverse Event Adjudication Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairman: Prof. Fang Qi, The First Affiliated Hospital of Soochow University</td>
</tr>
<tr>
<td>Members: Prof. Zhang Yongwei, Changhai Hospital Affiliated to the Second Military Medical University; Prof. Fu Jianhui, Huashan Hospital Affiliated to Fudan University</td>
</tr>
</tbody>
</table>

Version No.: 3.0; Date: August 20, 2019
Outcome Committee

Chairman: Prof. Li Yansheng, Renji Hospital of Shanghai Jiaotong University School of Medicine
Members: Prof. Zhang Ping, Changhai Hospital Affiliated to the Second Military Medical University; Prof. Zhang Yingying, Huadong Hospital Affiliated to Fudan University.

16.2 DIRECT-MT recommendations of the Steering Committee with regard to type of mechanical thrombectomy and use of thrombolytic agents during endovascular procedures.

General

Inclusion in the trial, randomization, and subsequent endovascular treatment with/without prior IVT should be started as soon as possible after presentation in all eligible patients.

The target time from study randomization to groin puncture will be as fast as possible. All patients would be better to undergo groin puncture within a median of 60 minutes after randomization.

Neuroimaging

Neuroimaging studies to assess vessel patency should be done before or simultaneously with treatment with intravenous (IV) alteplase, in order not to lose time and brain. We aim to not cause any delay prior to intra-arterial treatment, by infusion of IV alteplase.

Additional thrombolytic agents, dose and type

If deemed indicated by the interventionist, local application (intra-arterial) alteplase is allowed in any of the patients included in the DIRECT-MT.

Patients who have been pre-treated with IV alteplase should not receive more than 30 mg alteplase during intra-arterial treatment. The steering committee recommends that the alteplase is delivered in shots of 5 mg, in 5-10 minutes time intervals. In individual cases, an equivalent dose of 400,000 U urokinase, delivered in shots of 50,000 - 100,000 U, in 5-10 minutes time intervals, is also accepted as escape medication. Vessel patency should be checked after each shot.

Type of mechanical thrombectomy device(s)

All stent retriever and aspiration devices for IAT, which are approved for this purpose by CFDA, and have been approved for use in the study by the steering committee are allowed in the trial as a first line of defense and are listed below:

<table>
<thead>
<tr>
<th>Device name</th>
<th>Manufacturer</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solitaire</td>
<td>Medtronic / Covidien</td>
<td>Retrievable stent</td>
</tr>
<tr>
<td>Trevo</td>
<td>Stryker</td>
<td>Retrievable stent</td>
</tr>
<tr>
<td>Revive</td>
<td>Johnson &amp; Johnson/ Cerenovus</td>
<td>Retrievable stent</td>
</tr>
</tbody>
</table>
A second device is allowed as a second option, when the first device has failed according to the interventionist. The further choice of the particular device for a certain patient is left to the discretion of the interventionist.

### 16.3 Imaging requirements

#### 16.3.1 Minimum baseline imaging requirements

**When**

1) Before randomization, a NCCT and CTA should be performed to assess eligibility for the study.

**How**

1. **Pre-randomization NCCT:**
   
   1. The thickness of the NCCT scanning layer is recommended to be 5 mm, and 5-8 mm is also acceptable.
   
   2. The NCCT study should include the whole head.

2. **Pre-randomization CTA:**
   
   1. The CTA study should cover the whole area from the aortic arch to the vertex, and intracranial part only is also acceptable.
   
   2. The CTA study should include thin slices (maximum of 1.0 mm)
   
   3. The CTA study should include the following reconstructions
      
      i. Axial maximum intensity projection (MIP),
         
         1. MIP slab thickness: 25 mm
         
         2. Overlap: 5 mm
      
      ii. Coronal MIP
         
         1. MIP slab thickness: 25 mm
         
         2. Overlap: 5 mm

3. **After acquisition**
   
   1. All images (both NCCT and CTA) should be saved to the DICOM format
   
   2. All available series should be sent to the core lab for assessment, including thin slice series (for thrombus assessment).

#### 16.3.2 Intervention-related angiographic imaging

**When**

1) Before the intervention complete AP and Lateral angiograms (of whole head and including
venous phase) should be performed to evaluate the site of vessel occlusion, extent of thrombus, territories involved, concomitant pathologies and to assess collateral flow.

2) After each passage of a mechanical or aspirational device, a control angiogram should be performed.

3) After each bolus of (a rescue) thrombolytic agent, a control angiogram should be performed.

4) At the end of the procedure complete AP and Lateral angiograms (of whole head and including venous phase) should be repeated. Without these complete runs, optimal TICI scoring is not possible.

### How

**Pre-intervention and end-of-procedure angiogram:**

a. Angiograms should be performed through the guiding catheter

b. Baseline and final AP views and lateral views of the intracranial arteries are mandatory. Both are required to assess reperfusion after the procedure.

c. Baseline and final angiograms should include both the arterial and venous phases of the injection to evaluate the collateral pathways and perfusion of the distal vascular bed.

d. Baseline and final angiograms should include the internal carotid artery feeding the target vessel as demonstrated on CTA.

e. Baseline and final angiograms should include the common carotid and internal carotid artery in case of occlusion, dissection or severe stenosis in the carotid feeding the target vessel as demonstrated on CTA.

f. Angiograms should be performed via the guiding catheter with the same catheter position and same views before and after the procedures to adequately assess the results of therapy.

After each device placement:

- g. A non-contrast radiograph should be obtained

- h. At least one view at the discretion of the interventionalist

After each passage of mechanical or aspirational device or bolus of (rescue) thrombolytic agent:

- i. Angiograms should be performed through the guiding catheter

- j. At least one view, at the discretion of the interventionalist.

After the procedure:

- k. Complete series of the angiograms and microcatheter injections (when performed)
should be saved according to the DICOM standard.

I. All series should be forwarded to the imaging assessment committee.

### 16.3.3 Minimum follow-up imaging requirements

#### When

1) 24-72 hours after undergoing endovascular treatment, a NCCT and CTA should be performed to assess treatment efficacy.

2) 5-7 days after undergoing endovascular treatment, or before discharge a NCCT should be performed to assess final lesion volume and potential hemorrhages complications.

3) If clinically required (i.e. in cases of clinical deterioration of the patient) additional imaging as needed, at the discretion of the treating physician is acquired.

#### How

24-72 hours NCCT:

1. The thickness of the NCCT scanning layer is recommended to be 5 mm, and 5-8 mm is also acceptable.

2. The NCCT study should include the whole head.

24-72 hours CTA:

3. The CTA study should cover the whole area from the aortic arch to the vertex, and intracranial part only is also acceptable.

4. The CTA study should include thin slices (maximum of 1.0 mm)

5. The CTA study should include the following reconstructions
   
   i. Axial maximum intensity projection (MIP),
      
      1. MIP slab thickness: 25 mm
      2. Overlap: 5 mm
   
   ii. Coronal MIP

      1. MIP slab thickness: 25 mm
      2. Overlap: 5 mm

5-7 days NCCT (or before discharge)

6. The NCCT study should contain both thick (5mm) and thin slices (maximum of 2.5mm).

7. The NCCT study should include the whole head.

8. In addition, clinically required imaging is at the discretion of the treating physician.
9. After acquisition, all images (NCCT, CTA, and additional imaging) should be saved to the DICOM file format.

10. All available series should be sent to the core lab for assessment, including thin slice series (for thrombus assessment).